Fact-checked by Grok 2 weeks ago

Onchocerca volvulus

Onchocerca volvulus is a filarial parasitic nematode that causes onchocerciasis, a neglected tropical disease commonly known as river blindness, characterized by skin and eye pathology in humans.^[1]^[2] Belonging to the phylum Nematoda, class Chromadorea, order Rhabditida, family Onchocercidae, and genus Onchocerca, it is the sole species within its genus that infects humans.^[3] Adult worms, measuring 30–50 cm for females and 15–45 mm for males, reside in subcutaneous nodules formed in human hosts, where they can live for up to 15 years.^[1] Females produce millions of microfilariae over their ~9-year reproductive lifespan; these unsheathed larvae, 220–360 µm long, migrate through the skin and ocular tissues, causing intense pruritus, dermatitis, subcutaneous nodules, lymphadenopathy, and potentially irreversible vision loss if untreated.^[1]^[2] The life cycle of O. volvulus requires both human definitive hosts and blackfly (Simulium spp.) vectors as intermediate hosts.^[1] During a blood meal, infected female blackflies deposit third-stage infective larvae into the skin, which mature into adults over 6–12 months and form onchocercomas.^[1] Microfilariae ingested by feeding blackflies develop within the fly's tissues over 6–12 days into infective larvae, perpetuating transmission near fast-flowing rivers where vectors breed.^[1]^[2] Endemic in 30 countries as of 2025, primarily in 26 sub-Saharan African countries (over 99% of cases), with foci in three Latin American countries and Yemen, the parasite affects an estimated 21 million people as of 2017, with 1.15 million experiencing vision impairment and 14.6 million suffering skin disease; approximately 250 million people require preventive treatment.^[2]^[4] Significant progress has been made toward elimination, with the disease verified as eliminated in five countries, including Niger as the first in Africa in 2025.^[4] Diagnosis typically involves microscopic examination of skin snips for microfilariae or serological tests, while treatment relies on annual ivermectin mass drug administration to kill microfilariae and suppress transmission, aiming for elimination through sustained vector control and community programs.^[1]^[2]

Taxonomy and History

Taxonomy

Onchocerca volvulus belongs to the phylum Nematoda, class Chromadorea, order Rhabditida, family Onchocercidae, genus Onchocerca, and species volvulus.^[3] This classification places it among the filarial nematodes, characterized by their thread-like bodies and parasitic lifestyles in vertebrate hosts.^[3] The genus name Onchocerca derives from the Greek words onkos (meaning "hook" or "barb") and kerkos (meaning "tail"), referring to the hooked or barbed appearance of the microfilarial tails.^[5] The species name volvulus comes from the Latin word for "twisted" or "coiled," describing the tightly coiled adult worms.^[5] Within the genus Onchocerca, which primarily parasitizes ungulates, O. volvulus is unique as the only species specific to humans as definitive hosts.^[6] Closely related species include O. ochengi, a parasite of cattle in Africa that serves as a model for O. volvulus research due to their genetic and biological similarities, and O. lupi, which infects dogs and occasionally humans in a zoonotic capacity.^[7] These distinctions highlight O. volvulus's host specificity and its role in human disease.^[7]

Discovery

The microfilariae of Onchocerca volvulus were first observed in 1874 by British naval surgeon John O'Neill while examining skin snips from patients with a pruritic skin condition known as "craw craw" in the Gold Coast (present-day Ghana).^[5] These thread-like larvae were found in the skin but not identified as belonging to a specific species at the time. Subsequent investigations in the late 19th century focused on subcutaneous nodules, which were excised and studied; in 1893, German parasitologist Rudolf Leuckart described the adult worms from such nodules, formally naming the parasite Filaria volvulus (later reclassified as Onchocerca volvulus), establishing its morphological characteristics as a filarial nematode.^[8] The association between O. volvulus and the disease onchocerciasis, particularly its ocular manifestations, was established in 1915 by Guatemalan physician Rodolfo Robles, who examined patients with skin nodules, dermatitis, and anterior eye lesions containing microfilariae near fast-flowing rivers.^[9] Robles linked these symptoms to the parasite, noting the disease's prevalence in riverine communities near fast-flowing rivers, where blackfly breeding sites are located, though the vector role was not yet confirmed.^[9] This discovery highlighted onchocerciasis as a cause of blindness in Central America, prompting early recognition of its filarial etiology. Further milestones in understanding transmission occurred in 1926 when British parasitologist Donald Blacklock confirmed the role of the blackfly Simulium damnosum as the vector in Sierra Leone, demonstrating that infective larvae develop in the fly after ingestion of microfilariae from human skin.^[5] Post-World War II efforts in the 1950s and 1960s, including extensive surveys by colonial medical services and the World Health Organization across West and Central Africa, mapped the parasite's widespread distribution, revealing hyperendemic foci and informing initial vector control trials with insecticides like DDT.^[10] In the 2000s, the World Health Organization classified onchocerciasis as a neglected tropical disease, emphasizing its disproportionate impact on impoverished riverine populations in Africa and the Americas.^[2] In 2007, WHO endorsed a strategy for elimination through ivermectin treatment. This designation spurred global commitments, including elimination goals set through the 2012 London Declaration on Neglected Tropical Diseases, with goals updated in the WHO 2021-2030 NTD Roadmap to achieve elimination as a public health problem by 2030 in all endemic regions.^[2]^[11]

Morphology and Life Cycle

Morphology

Onchocerca volvulus is a dioecious filarial nematode, with adult worms exhibiting pronounced sexual dimorphism in size and habitat. Adult females measure 300–500 mm in length and 0.25–0.4 mm in width, typically coiled within subcutaneous nodules known as onchocercomas.^[12]^[1] Adult males are smaller, ranging from 15–45 mm in length and 0.15–0.2 mm in width, and are more mobile, often traversing the skin between nodules to locate females.^[12]^[1] The microfilariae, the first-stage larvae produced by gravid females, are unsheathed and measure 220–360 μm in length, with a pointed tail and remnants of the eggshell sheath.^[13]^[1] Unlike the microfilariae of some other filariae such as Wuchereria bancrofti, which exhibit periodicity in the blood, those of O. volvulus are non-periodic and primarily reside in the skin.^[1] Key anatomical features include a cuticle adorned with fine transverse striae, a diagnostic trait visible under microscopy, along with cephalic amphids for sensory function and caudal phasmids.^[14] Females are ovoviviparous, retaining developing embryos in utero until they hatch into active microfilariae, which are then released larviparously. Nutrient uptake occurs primarily through diffusion from host tissues or direct access to blood vessels, with the worms inducing host angiogenesis to vascularize the surrounding nodule and ensure sustained nourishment.^[15] Sexual dimorphism extends to reproductive structures: males possess paired spicules used for copulation, while the female vulva is positioned near the anterior end, shortly behind the esophagus.^[16] These features facilitate mating within the confined nodule environment.

Life Cycle

The life cycle of Onchocerca volvulus is complex and digenetic, requiring both a human definitive host and a blackfly intermediate host of the genus Simulium for completion. Adult worms reside in the human host for up to 15 years, with females measuring 30–50 cm in length and producing approximately 1,000–1,500 microfilariae per day over their reproductive lifespan of about 9 years.^[17]^[1] These microfilariae are the infective stage for the vector and migrate through the skin, where they can survive for up to 2 years if not ingested by a blackfly.^[1] In the human host, third-stage infective larvae (L3), measuring 440–700 μm in length, are introduced into the skin through the bite of an infected Simulium blackfly. These larvae migrate subcutaneously and undergo molting to the fourth stage (L4) before maturing into adults within 6–12 months.^[18] The adult worms, both males (2–5 cm) and females, pair and form fibrous nodules (onchocercomas) in subcutaneous tissues, often in areas such as the pelvis, limbs, or head. Fertilized females then release unsheathed microfilariae (220–360 μm long, 5–9 μm wide) into the surrounding skin and connective tissues, where they remain motile for months to years.^[17]^[1] The prepatent period—from initial infection to the appearance of microfilariae in the skin—is typically 12–18 months.^[19] In the blackfly vector, microfilariae are ingested during a blood meal from an infected human and penetrate the midgut within hours. They migrate to the hemocoel and then to the thoracic flight muscles, where development proceeds: initial differentiation to first-stage larvae (L1) occurs within about 2–4 days, molting to second-stage larvae (L2) follows shortly after, and a second molt produces infective L3 larvae by 7–9 days post-ingestion at temperatures of 20–25°C.^[18] The L3 larvae then migrate to the blackfly's head and proboscis over the next few days, ready for transmission to a new human host during the vector's next blood meal. The entire extrinsic incubation period in the blackfly typically lasts 1–3 weeks, depending on temperature and species.^[17]^[20] Transmission is optimized in environments near fast-flowing rivers and streams, where Simulium blackflies breed, with higher activity in humid, tropical regions supporting the parasite's development.^[2]

Onchocerciasis

Pathogenesis

The pathogenesis of Onchocerca volvulus infection primarily involves the host's immune response to the parasite's microfilariae and adult worms, leading to localized and systemic tissue damage.^[17] Microfilariae, the larval stage produced by adult female worms, are unsheathed and migrate through the skin and subcutaneous tissues, causing mechanical irritation that triggers an inflammatory response.^[1] This migration into the anterior chamber of the eye can induce keratitis through direct penetration and subsequent immune-mediated inflammation, while accumulation in ocular tissues promotes sclerosing chorioretinitis via eosinophil infiltration and degranulation.^[21] Adult worms, residing in subcutaneous nodules known as onchocercomas, elicit a granulomatous reaction characterized by fibrosis and encapsulation, which traps the worms and limits their spread but contributes to chronic inflammation.^[22] The formation of these nodules results from continuous stimulation by parasite antigens, including those from the endosymbiotic bacterium Wolbachia, leading to a dense infiltrate of inflammatory cells around the worms.^[23] Hypoxia within the nodules may exacerbate pathogenesis by promoting the release of Wolbachia components, intensifying the host's immune activation.^[24] Key inflammatory pathways are driven by Wolbachia surface protein (WSP) and bacterial DNA, which activate Toll-like receptor 4 (TLR4) on host immune cells, initiating a cascade of cytokine release and neutrophil recruitment.^[25] Eosinophils, central to the response, degranulate to release major basic protein, which damages surrounding tissues including skin and ocular structures through toxic effects on collagen and epithelial cells.^[26] These pathways are TLR2- and TLR4-dependent, underscoring the role of innate immunity in amplifying parasite-induced pathology.^[27] Systemic effects, though less common, include potential neuroinflammation linked to nodding syndrome, where microfilariae may cross the blood-brain barrier, triggering autoimmune responses via cross-reactive antibodies against O. volvulus antigens.^[28] This leads to distinct immune profiles in cerebrospinal fluid, with elevated complement activation and pro-inflammatory markers contributing to neurological damage.^[29] Lymphatic involvement is minimal compared to other filarial infections, with pathology primarily confined to dermal and ocular sites.^[2]

Clinical Manifestations

Onchocerciasis, caused by infection with Onchocerca volvulus, presents a spectrum of clinical manifestations ranging from asymptomatic carriage to severe, debilitating disease, with severity influenced by infection intensity, host immune responses, and duration of exposure.^[17] Many individuals harbor microfilariae without noticeable symptoms, while others develop progressive pathology due to inflammatory reactions to the parasites.^[30] The disease course typically evolves over years, beginning with subtle skin involvement and potentially advancing to irreversible organ damage if untreated.^[24] Acute manifestations often include intense pruritus resulting from microfilariae migrating through the skin, which can lead to severe itching and secondary excoriations.^[2] Subcutaneous nodules, known as onchocercomas, form around adult worms and are firm, painless, and movable; they commonly appear over bony prominences such as the hips, buttocks, iliac crests, or head in African foci.^[17] These nodules may be single or multiple and persist for up to 15 years, containing coiled adult worms that produce microfilariae.^[1] Chronic skin changes, collectively termed onchodermatitis, encompass a range of dermatological alterations driven by repeated inflammatory responses to dying microfilariae.^[31] These include lichenified onchodermatitis with thickened, leathery skin from chronic scratching; atrophic changes leading to thin, wrinkled skin; and depigmented patches known as "leopard skin," characterized by spotted hypopigmentation often on the lower limbs.^[17] Secondary bacterial infections frequently complicate these lesions due to breaches in the skin barrier, exacerbating pruritus and inflammation.^[31] Ocular involvement arises from microfilariae invading the eye, initiating inflammatory cascades that progress over years.^[21] Early signs include punctate keratitis, manifesting as fluffy, snowflake-like opacities in the cornea, and iridocyclitis with anterior uveitis causing pain, redness, and photophobia.^[17] Advanced stages feature sclerosing keratitis with corneal scarring, optic atrophy, and chorioretinal lesions, culminating in irreversible blindness in approximately 1–10% of long-term infections in hyperendemic areas.^[2] Additional complications encompass lymphadenopathy, with enlarged, tender lymph nodes often in the inguinal or femoral regions due to microfilarial infiltration.^[1] Less commonly, elephantiasis-like edema and fibrosis may develop in the limbs or genitals, resembling "hanging groin" from chronic lymphatic obstruction.^[32] In endemic regions, onchocerciasis has been associated with nodding syndrome, an epilepsy-like condition featuring head-dropping seizures in children, potentially linked to neuroinflammatory responses.^[33] Post-treatment, the Mazzotti reaction can occur as an acute complication from dying microfilariae, presenting with fever, rash, arthralgia, and hypotension.^[17]

Diagnosis

Diagnosis of Onchocerca volvulus infection primarily relies on detecting microfilariae, adult worms, or specific immune responses in affected individuals, with methods varying by clinical context and program needs for elimination surveillance.^[34] Parasitological techniques remain foundational, while serological and molecular assays offer enhanced sensitivity in low-prevalence settings.^[35] Parasitological tests include skin snipping, considered the gold standard for confirming active infection through direct visualization of microfilariae.^[34] In this procedure, small skin biopsies (typically 1-2 mg each) are taken from sites such as the iliac crests or calves using a scleroderma punch or razor blade, weighed, and incubated in saline; the emerging microfilariae are then counted under a microscope to determine density in microfilariae per milligram of skin (mf/mg).^[17] This method provides high specificity but variable sensitivity (29-76% post-mass drug administration), limiting its utility in low-endemic areas where microfilarial loads are reduced.^[35] Nodule palpation and excisional biopsy allow detection of adult worms, with nodules surgically removed and dissected to identify coiled macrofilariae, aiding diagnosis in cases of high suspicion despite negative skin snips.^[1] Serological assays detect antibodies against O. volvulus-specific antigens, useful for assessing exposure or active infection without invasive procedures. The Ov-16 IgG4 enzyme-linked immunosorbent assay (ELISA), performed on serum or dried blood spots, is highly sensitive for detecting exposure in children under 10 years and is recommended by the World Health Organization for transmission interruption verification, with reported sensitivity of 88.2% and specificity of 99.7%.^[36]^[37] The Ov-29 antigen-based ELISA targets IgG responses for identifying active infection, particularly in microfilariae-negative individuals, improving specificity when combined with other antigens like Ov-11 or Ov-27.^[38] Polymerase chain reaction (PCR) methods, such as the O-150 PCR assay, amplify O. volvulus DNA from skin snips or blood, offering near-100% sensitivity and specificity to enhance detection in low-density infections.^[39]^[35] Ocular examinations are essential for diagnosing eye involvement in onchocerciasis. Slit-lamp biomicroscopy of the anterior segment reveals microfilariae in the cornea or anterior chamber, often after a head-down position to facilitate migration, and identifies lesions like punctate keratitis or sclerosing keratitis.^[17] Fundoscopy assesses posterior segment pathology, detecting chorioretinitis, optic nerve atrophy, or retinal changes through direct visualization or adjuncts like optical coherence tomography.^[17] For community-level surveillance and mapping, tools like the Ov-16 rapid diagnostic test (RDT) enable point-of-care detection of IgG4 antibodies on finger-prick blood, with field sensitivity of 81.1-81.3% and specificity of 99-100%, supporting hypoendemic area delineation.^[35] The PoolScreen PCR (O-150 PCR) on pools of blackfly heads detects infective larvae DNA, screening up to 100 flies per pool with high efficiency to monitor transmission below 0.05% prevalence, as required for elimination certification.^[40]^[35] Diagnostic challenges persist, particularly in low-endemic areas where test sensitivity declines due to sparse microfilariae, necessitating highly specific assays to minimize false positives and requiring trained personnel for procedures like skin snipping or entomological sampling.^[35]^[41]

Treatment

The primary pharmacological intervention for onchocerciasis due to Onchocerca volvulus is ivermectin, a microfilaricide given as a single oral dose of 150–200 μg/kg, typically administered annually or semi-annually to reduce microfilarial loads in the skin and eyes.^[42]^[43] Ivermectin rapidly kills microfilariae but spares adult worms, necessitating repeated dosing over 10–15 years to interrupt transmission.^[42] Since 1987, ivermectin has been donated free through the Mectizan Donation Program by Merck & Co., enabling widespread access in endemic regions.^[19] To target adult worms (macrofilaricides), doxycycline is administered at 100–200 mg/day for 4–6 weeks, depleting the essential Wolbachia endosymbiont and inducing long-term sterilization of female worms, with effects lasting up to 18 months or more.^[42]^[44] This approach reduces microfilarial production but is unsuitable for mass campaigns due to the extended regimen and potential side effects like gastrointestinal upset.^[45] Surgical nodulectomy involves excising palpable subcutaneous nodules harboring adult worms, which can lower microfilarial output by 65% or more and curb transmission, particularly in low-prevalence foci or when nodules are onchocercomas near the head.^[46]^[47] Emerging macrofilaricidal therapies include moxidectin, approved by the U.S. FDA in 2018 for patients aged 12 and older, which suppresses skin microfilariae for up to 18 months—longer than ivermectin—while maintaining a similar safety profile. In January 2025, Ghana initiated the world's first community-based rollout of moxidectin for onchocerciasis treatment in selected areas to address ongoing transmission.^[48]^[49] Emodepside, an investigational anthelmintic, is in Phase II trials (initiated in 2022), with encouraging safety and efficacy results from part 1 reported in 2025, demonstrating promising adult worm-killing activity and tolerability in human studies as of November 2025.^[50] A Phase IIa proof-of-concept trial for oxfendazole, a benzimidazole with macrofilaricidal potential, commenced in 2025 to assess its efficacy and safety in onchocerciasis-endemic areas.^[51] Suboptimal ivermectin responses, indicative of emerging resistance, were documented in Ghana in 2023 studies, where microfilarial repopulation occurred faster than expected despite repeated dosing.^[52] Management of such cases involves intensified regimens, including triple therapy with ivermectin, albendazole, and doxycycline to synergistically target microfilariae, adults, and Wolbachia.^[46] Treatment can provoke the Mazzotti reaction—intense itching, fever, hypotension, and lymphadenopathy from dying microfilariae—which is managed with antihistamines for pruritus and low-dose corticosteroids tapered rapidly to control inflammation.^[46]^[53]

Prevention and Control

The primary strategy for preventing and controlling Onchocerca volvulus infection, which causes onchocerciasis, is mass drug administration (MDA) using ivermectin. This involves distributing ivermectin annually or biannually to all eligible individuals over 5 years of age in endemic communities, aiming for therapeutic coverage of at least 80% to interrupt transmission.^[2]^[11] Ivermectin targets microfilariae, reducing the parasite load in humans and thereby limiting the infectious reservoir for blackfly vectors. Community-directed treatment programs, where local health workers and volunteers manage distribution, enhance sustainability and coverage in remote areas.^[54] Vector control complements MDA by targeting Simulium blackfly breeding sites in fast-flowing rivers. Larvicides such as temephos are applied to water bodies to kill immature blackflies, while biological agents like Bacillus thuringiensis israelensis offer environmentally safer alternatives by producing toxins specific to fly larvae. Personal protective measures, including insecticide-treated nets and repellents, provide additional protection against bites, particularly in high-transmission zones.^[11]^[55] Surveillance is essential for monitoring progress and deciding when to stop MDA. Ov-16 serology, detecting IgG4 antibodies against the O. volvulus recombinant antigen Ov-16 in children aged 5-10 years, serves as a key indicator of recent transmission; prevalence below 0.1% (upper 95% confidence limit) in this group supports decisions to stop MDA and verify transmission interruption. Entomological surveillance involves capturing and testing blackflies for O. volvulus larvae using PCR on pooled samples to assess vector infectivity rates.^[56]^[57]^[55]^[54] Integrated approaches enhance efficiency by combining onchocerciasis control with efforts against other neglected tropical diseases, such as lymphatic filariasis, through co-administration of ivermectin and albendazole during MDA rounds. This synergy reduces logistical costs and improves community engagement via unified campaigns led by trained health workers.^[58]^[59] Challenges include co-endemicity with Loa loa in central Africa, where high microfilarial loads can cause severe adverse events (SAEs) like encephalopathy following ivermectin treatment, necessitating test-and-not-treat strategies using point-of-care Loa loa microfilaria detection before MDA. Post-elimination surveillance remains critical to detect recrudescence, requiring sustained entomological and serological monitoring for at least 3-5 years after stopping interventions.^[60]

Epidemiology

Distribution

Onchocerca volvulus is predominantly distributed in sub-Saharan Africa, where over 99% of infections occur across 26 countries, with additional endemic foci in Yemen and limited areas of Latin America.^[2] The parasite's transmission is closely tied to specific ecological niches, primarily in regions near fast-flowing rivers and streams that support the breeding of its intermediate host vectors, creating characteristic riverine transmission zones.^[2] Within Africa, two main strains of O. volvulus are recognized: the savanna strain, prevalent in drier grassland areas and associated with more severe ocular pathology, and the forest strain, found in humid rainforest regions and linked to milder disease manifestations.^[20] The introduction of O. volvulus to the Americas occurred during the transatlantic slave trade between the 16th and 19th centuries, resulting in isolated foci in regions such as Chiapas in Mexico and parts of the Amazon basin.^[61] These New World populations represent a subset of the parasite's global range, genetically distinct from African strains but originating from West African sources.^[62] As of 2025, the distribution in Latin America has contracted significantly, with elimination verified in Colombia, Ecuador, Mexico, and Guatemala, leaving small residual foci in Brazil and Venezuela.^[2] In Africa, hyperendemic areas persist in countries including Nigeria, the Democratic Republic of the Congo, and Ethiopia, where transmission remains intense near major river systems. Yemen continues to harbor endemic foci, primarily in mountainous regions with suitable aquatic habitats.^[2]

Transmission and Prevalence

Onchocerciasis, caused by the filarial nematode Onchocerca volvulus, affects an estimated 21 million people, primarily in sub-Saharan Africa. Among those infected, about 1.15 million individuals suffer from vision loss due to the disease. In hyperendemic foci, microfilarial prevalence typically ranges from 40% to over 80%, reflecting high community-level transmission intensity.^[2]^[63]^[2]^[64] Transmission occurs exclusively through the bites of infected female blackflies of the genus Simulium, which breed in fast-flowing rivers and streams. In high-transmission areas, annual blackfly biting rates can reach 1,000 or more bites per person, facilitating the uptake of skin-dwelling microfilariae from infected humans—the sole reservoir—and their development into infective larvae within the vector. Biting activity exhibits seasonal peaks during the rainy season, when river flows support blackfly breeding and dispersal, often from May to October in West and Central Africa.^[2]^[65]^[2]^[66] Key risk factors for infection include residential proximity to breeding sites, with elevated rates observed among individuals living less than 5 km from rivers. Infection prevalence peaks in adults aged 20–40 years, coinciding with occupational exposure, and is generally higher in males due to greater outdoor activities near water bodies. Co-infection with Loa loa poses significant challenges to mass drug administration (MDA) programs, as high L. loa microfilarial loads can trigger severe adverse events following ivermectin treatment, necessitating alternative strategies in co-endemic regions.^[17]^[17]^[17]^[67] O. volvulus exhibits strain variations that influence disease presentation and transmission efficiency, with the savanna strain predominant in drier regions and associated with severe ocular involvement leading to blindness, while the forest strain in humid areas primarily causes skin manifestations. These strains are distinguished by genetic markers, such as sequence variations in mitochondrial and nuclear genes, which correlate with adaptation to specific blackfly vector species and ecological niches.^[68]^[20]^[69] Recent epidemiological trends show substantial declines in prevalence across Africa attributable to sustained MDA with ivermectin, reducing microfilarial loads and interrupting transmission in many foci. However, hotspots persist in remote or conflict-affected areas, with recrudescence reported in Nigeria as of 2025, underscoring the need for intensified surveillance and targeted interventions.^[70]^[71]

Elimination Progress

Significant progress has been made in eliminating onchocerciasis transmission in the Americas through the Onchocerciasis Elimination Program for the Americas (OEPA), launched in 1992. Colombia achieved verification of elimination in 2013, followed by Ecuador in 2014, Mexico in 2015, and Guatemala in 2016, marking these as the first countries worldwide to interrupt transmission. In Africa, Niger became the first country to achieve verified elimination on January 30, 2025.^[72]^[73]^[74]^[75]^[76] Brazil completed 36 effective biannual rounds of mass drug administration (MDA) with ivermectin through 2022, initiating post-treatment surveillance thereafter.^[77] As of 2025, residual transmission persists in a small number of communities in Brazil and Venezuela.^[2] In Africa, where over 99% of cases occur, elimination efforts face greater challenges, leading the World Health Organization (WHO) to shift its original 2025 target—set under the African Programme for Onchocerciasis Control—to a 2030 goal as outlined in the NTD Roadmap 2021–2030.^[2] The 2024–2025 WHO progress report indicates that effective MDA coverage reached 88% across endemic implementation units, with transmission interrupted in parts of Uganda and Sudan, among other countries like Equatorial Guinea, Ethiopia, Mali, Nigeria, Tanzania, and Togo that have stopped MDA in select foci.^[4]^[2] Verification of elimination requires no evidence of transmission for 12–16 years after stopping MDA, confirmed by Ov-16 seroprevalence below 0.1% (upper 95% confidence limit) in children under 10 years and entomological assessments showing fewer than 0.05% infective larvae (O-150 PCR) in at least 6,000 black flies per transmission zone.^[78] Despite these advances, challenges persist, including the emergence of sub-optimal responses to ivermectin in Ghana reported in 2023 studies, ongoing transmission in conflict-affected areas like the Democratic Republic of Congo, and recrudescence detected in Nigeria in a 2025 study in Kaduna State.^[79]^[80] These issues, compounded by co-endemicity with loiasis and limited access in remote zones, underscore the need for new macrofilaricidal drugs and enhanced diagnostics. Looking ahead, the WHO's 2030 target emphasizes integrating onchocerciasis control with other neglected tropical diseases to sustain high coverage and achieve verification in at least 10 countries.^[2]^[81]

Genetics and Symbiosis

Genome

The nuclear genome of Onchocerca volvulus spans approximately 95 megabase pairs (Mb) and is organized into four pairs of chromosomes, consisting of three autosomal pairs and a pair of sex chromosomes, with females exhibiting an XX karyotype and males an XY system of sex determination, featuring a small Y chromosome.^[82] This structure reflects a compact genome typical of filarial nematodes, with an AT content of about 70% (GC content of 30.2%), which contributes to challenges in sequencing and assembly due to repetitive regions.^[82] Bioinformatic annotation has identified around 12,143 protein-coding genes, guided by RNA sequencing data across multiple life stages, representing a refined count from earlier estimates of up to 16,000 genes based on expressed sequence tags.^[82]^[83] The mitochondrial genome is a circular DNA molecule of 13,747 base pairs (bp), encoding 12 protein-coding genes, 22 transfer RNA (tRNA) genes, and 2 ribosomal RNA (rRNA) genes, with a notable AT bias in codon usage that supports its utility in phylogenetic studies of filarial parasites.^[84] Unlike the nuclear genome, the mitochondrial sequence lacks introns and exhibits minimal intergenic regions, facilitating complete assembly and comparison across Onchocerca species.^[84] Key genomic features include expanded gene families involved in parasite-host interactions, such as those encoding cuticular surface proteins like collagens, which form the protective exoskeleton and vary across life stages to evade host immunity.^[82] Glutathione S-transferases (GSTs), particularly the extracellular OvGST1 isoforms, represent another prominent family, functioning in detoxification of reactive oxygen species and potentially modulating host inflammatory responses.^[85] The genome shows no evidence of functional Wolbachia-integrated genes (nuwts), with over 500 putative integrations identified as fragmented and non-coding remnants.^[82] Additionally, cytogenetic and synteny analyses suggest chromosome fusion events, particularly involving autosome 1 and the X chromosome, which arose from ancestral recombinations and influence gene density patterns.^[82] Sequencing efforts began with a draft assembly in 2012 by the Broad Institute, utilizing short-read Illumina data to produce an initial contig-based reference (GCA_000180695.1) that covered much of the genome but suffered from fragmentation in repetitive areas.^[86] This was substantially improved in 2016 through a collaborative effort at the Wellcome Trust Sanger Institute, incorporating long-read optical mapping, fosmid libraries, and manual curation to achieve chromosome-level resolution for the first time in a parasitic nematode.^[82] Population genomic analysis of whole-genome sequences from 27 isolates, collected in the early 1990s from diverse locales including Ecuador, Uganda, Cameroon, and Ghana, revealed remarkably low nucleotide diversity (π ≈ 1.79 × 10⁻³), consistent with a history of population bottlenecks and limited gene flow.^[62] A 2025 genome-wide study further confirmed fine-scale genetic structuring across regions and hosts, with ongoing low diversity indicative of persistent bottlenecks despite control efforts.^[87] Functional annotation highlights genes critical for parasite survival and reproduction, including an expanded family of 16 collagen prolyl 4-hydroxylase paralogs essential for embryogenesis and eggshell formation during microfilarial development.^[82] For immune evasion, the genome encodes multiple venom allergen-like proteins (VALs), such as Ov-ASP-1, which are secreted by infective larvae to suppress host Th2 responses and promote parasite migration into skin tissues.^[88] Other evasion mechanisms involve protease inhibitors, including 12 serpins and 5 cystatins, which inhibit host proteolytic cascades and cytokine signaling to dampen inflammation.^[82]

Wolbachia Endosymbiont

Onchocerca volvulus harbors an obligate intracellular endosymbiont from the genus Wolbachia, designated as strain wOv, which belongs to supergroup F and is essential for the nematode's biology. This gram-negative bacterium is maternally inherited, transmitted vertically through the egg cytoplasm of female worms, ensuring its persistence across generations. The complete genome of wOv, sequenced in 2016, spans approximately 956 kb and encodes 785 protein-coding genes, reflecting the reduced genome typical of obligate endosymbionts adapted to intracellular life.^[89]^[90] wOv localizes intracellularly within the hypodermal lateral chords, ovaries, and developing embryos of O. volvulus, with bacterial density varying across life stages and peaking in adult worms. This distribution supports the bacterium's role in reproductive processes, as it is nearly absent in mature microfilariae but abundant in gravid females, facilitating transmission to offspring. The symbiosis is mutualistic, with wOv providing critical metabolic support to the nematode, including heme biosynthesis via enzymes like ferrochelatase and protection against oxidative stress through antioxidants such as catalase and glutathione-related pathways; in turn, the nematode supplies nutrients to the bacterium. Absence of wOv, as induced experimentally, results in infertility, halted embryogenesis, and eventual worm death, underscoring its indispensability for filarial development and fertility.^[90]^[91] Therapeutically, wOv serves as a target for antibiotics that disrupt the symbiosis, with doxycycline (200 mg/day for 4–6 weeks) depleting over 90% of the bacteria, leading to sterilization of adult worms and suppression of microfilariae production for 1–2 years post-treatment. This macrofilaricidal effect complements ivermectin by addressing adult parasites directly. Alternatives like rifampicin have been explored, showing comparable Wolbachia depletion in shorter regimens (2–4 weeks), though with variable efficacy in clinical settings.^[92]^[93] Recent research, including a 2021 comprehensive review, highlights the spectrum of Wolbachia endosymbiosis in onchocercid nematodes, emphasizing wOv's conserved mutualistic traits without major genomic updates between 2020 and 2025. However, studies continue to elucidate its role in pathogenesis, where bacterial surface proteins trigger inflammatory responses via Toll-like receptor 2, contributing to tissue damage in onchocerciasis.^[90]^[94]

Evolution

Phylogenetic Relationships

Onchocerca volvulus belongs to the family Onchocercidae within the superfamily Filarioidea, order Rhabditida, and phylum Nematoda.^[89]^[3] This positioning places it among vector-borne filarial nematodes that parasitize vertebrates, with the genus Onchocerca comprising species infecting ungulates and humans.^[95] Within the genus, O. volvulus is most closely related to O. ochengi, a parasite of cattle in Africa, based on morphological, molecular, and life cycle similarities.^[96] Other close relatives include zoonotic species such as O. lupi, which infects canids and occasionally humans, highlighting potential cross-species transmission risks.^[97] The divergence of O. volvulus from lymphatic filariae like Wuchereria bancrofti reflects an ancient split in filarial evolution tied to differing host and vector adaptations.^[98] In the broader filarial clade, *O. volvulus* shares key morphological traits with other human filariae, including cuticular striae and microfilarial sheath structures that facilitate vector transmission.^[99] Mitochondrial phylogenomics, utilizing complete mitochondrial genomes, robustly confirm the monophyly of Onchocercidae, positioning O. volvulus within a well-supported clade of subcutaneous filariae distinct from lymphatic and heartworm genera.^[100] These analyses, based on concatenated datasets of ribosomal and protein-coding genes, underscore conserved mitochondrial gene arrangements across filariae, supporting their evolutionary cohesion despite host specificity.^[101] The parasite's adaptation to blackfly vectors (Simulium spp.) reflects co-evolution, with O. volvulus microfilariae optimized for development in specific Simulium subgenera, influencing transmission dynamics.^[102] This association is inferred to be ancient, drawing from fossil records of nematoceran Diptera (including Simuliidae ancestors) dating back to the Eocene, suggesting a long-term parasite-vector linkage predating modern host-parasite complexes.^[103] Comparative genomics of O. volvulus reveals conserved spirurid genes essential for parasitism, such as those involved in cuticle formation and immune evasion, as highlighted in the 2012 draft genome assembly.^[86] This assembly identified orthologues shared with other Spirurida, comprising over 90% of predicted protein-coding genes, with expansions in gene families like G-protein coupled receptors linked to sensory adaptations in filarial lifestyles.^[89] Recent genomic studies from 2020–2025, including a 2024 revision identifying cryptic Onchocerca species in ungulates, have refined genus-level phylogeny but maintained the established positioning of O. volvulus within filarial relationships.^[104]^[105]

Genetic Diversity and Host Shift

Onchocerca volvulus displays low levels of nuclear genetic diversity, characterized by a genome-wide nonsynonymous nucleotide diversity (π_N) of approximately 0.001, consistent with a historical population bottleneck.^[62] This contrasts with higher mitochondrial DNA variation, where analyses of pooled microfilariae have identified over 150 unique haplotypes across 189 samples from West African foci, reflecting greater maternally inherited diversity.^[106] Genetic differentiation between savanna and forest strains is evident, with an F_ST of 0.04 and elevated single nucleotide polymorphism (SNP) frequencies in specific genomic regions, including 194 autosomal outlier windows associated with 300 genes that support the classical two-strain model.^[62] Evidence for bottlenecks is drawn from pre-mass drug administration (MDA) samples collected in the 1990s, which exhibit founder effects, particularly in the Ecuadorian population linked to a single introduction event and positive Tajima's D values indicative of reduced variation.^[62] Post-bottleneck expansion is supported by recent genomic data showing negative Tajima's D values ranging from -0.4 to -2.3 across African regions, suggesting rapid population recovery following historical contractions.^[87] The evolutionary origins of O. volvulus involve a hypothesized host shift from bovine filariae, such as Onchocerca ochengi, around 10,000 years ago, aligning with the domestication of cattle in sub-Saharan Africa and divergence from a common ancestor.^[107] Zoonotic potential within the genus is highlighted by human cases of Onchocerca lupi infection, an emerging canine parasite, as reviewed in a 2020 study documenting ocular and subcutaneous manifestations in affected individuals.^[108] A 2019 preprint (published 2023) underscored the utility of whole mitochondrial genome sequencing for delineating transmission zones, revealing genetic homogeneity within central Ghana (ϕ_PT not significant) but differentiation from neighboring countries like Côte d'Ivoire (ϕ_PT = 0.018, P < 0.001).^[106] No substantial updates on genetic diversity patterns have appeared from 2023 to 2025, though a 2025 genome-wide study of 306 microfilariae confirmed persistently low autosomal π (0.0022) and reinforced the role of such metrics in elimination monitoring, highlighting limited evolutionary adaptability that may facilitate eradication by reducing potential for resistance development.^[87] This limited genetic variability implies reduced adaptability in O. volvulus, potentially easing eradication efforts by diminishing the parasite's capacity for evolutionary responses to interventions like ivermectin-based MDA and lowering risks of resurgence from diverse genetic pools.^[87]

Immunology

Human Immune Response

The innate immune response to Onchocerca volvulus infection primarily involves the recruitment of eosinophils and macrophages to sites of parasite localization in the skin and eyes. Eosinophils target larval stages and microfilariae through degranulation and antibody-dependent mechanisms, while macrophages accumulate around adult worms in subcutaneous nodules and contribute to granulomatous inflammation.^[15]^[109] Toll-like receptors TLR2 and TLR6 recognize lipopolysaccharide from the endosymbiotic Wolbachia bacteria within the parasite, initiating pro-inflammatory signaling via MyD88 and leading to cytokine release such as TNF-α and IL-6, which amplify local inflammation. Complement activation is triggered during infection, with C3b deposition on microfilariae promoting opsonization and phagocytosis by immune cells. The adaptive immune response is characterized by a Th2-dominated profile, with elevated production of cytokines IL-4, IL-5, and IL-10 that drive eosinophilia, mast cell activation, and B-cell responses. These cytokines foster a state of hyporesponsiveness in chronic infection, allowing parasite persistence while limiting excessive tissue damage. Specific antibodies, including IgE and IgG4, target microfilarial antigens such as Ov39, with IgE facilitating eosinophil-mediated killing and IgG4 associated with immune modulation in heavily infected individuals.^[15]^[112]^[109] Age-related shifts in the immune response to O. volvulus show robust Th2 activity and high antibody levels in younger individuals, which decline after age 40, coinciding with reduced microfilarial intensity and increased activity of regulatory T cells that suppress pro-inflammatory pathology. This waning response contributes to higher infection prevalence in older adults due to immunosenescence, including decreased naive T-cell function and altered cytokine balance favoring IL-10 over protective IL-5. Protective immunity against reinfection develops over time, limiting new larval establishment, though it permits chronic adult worm survival; genetic factors, such as HLA class II alleles (e.g., DQA10501-DQB10301 associated with putative immunity and DQB1*0201 with generalized disease), influence response vigor and disease severity. Recent animal model studies of vaccination against O. volvulus have shown that protective immunity can be mediated by IgG antibodies dependent on neutrophils and complement activation.^[113]^[114]^[115]

Parasite Immune Evasion

Onchocerca volvulus employs a multifaceted array of immune evasion strategies to establish chronic infections in humans, primarily targeting both innate and adaptive immune responses. These mechanisms enable the parasite's microfilariae and adult worms to persist despite ongoing host immunity, contributing to the disease's long-term nature. Key tactics include modulation of the complement system, induction of regulatory T cells, impairment of antigen-presenting cells, and secretion of immunomodulatory molecules such as protease inhibitors and cytokine homologues.^[116]^[15] One primary evasion mechanism involves the sequestration of host complement regulator Factor H by microfilariae, which binds directly to the parasite surface to inhibit the alternative complement pathway and prevent opsonization and lysis. This binding conceals surface antigens and disrupts complement-mediated immune attack, as demonstrated in studies showing Factor H recruitment to microfilarial sheaths.^[117] Additionally, the formation of circulating immune complexes between parasite antigens and host antibodies masks epitopes, potentially evading antibody-dependent cellular cytotoxicity and reducing effective humoral responses. O. volvulus also suppresses adaptive immunity through the induction of regulatory T cells (Tregs), including antigen-specific Tr1 cells that express high levels of CTLA-4 to inhibit effector T-cell proliferation and cytokine production. This leads to dampened Th1 and Th2 responses, favoring parasite survival in chronic infections. Expansion of CD4+CD25+ Tregs further promotes immunosuppression by downregulating classical Th2 immunity, with elevated CTLA-4 expression correlating with reduced protective responses in infected individuals.^[118]^[119]^[120] The parasite impairs innate immune activation by targeting dendritic cells (DCs), key antigen-presenting cells. Soluble extracts from O. volvulus induce apoptosis in monocyte-derived DCs, limiting their maturation and ability to prime T cells. Furthermore, filarial antigens inhibit DC differentiation from monocytes and impair their function in presenting antigens to T cells, thereby reducing overall immune priming.^[121]^[122] Secreted molecules further enhance evasion. Antioxidative enzymes, including glutathione peroxidase (GPX-1), superoxide dismutase (SOD-2), thioredoxin peroxidase (TPX-1 and TPX-2), and glutathione S-transferase (GST-1), neutralize reactive oxygen species from host eosinophils, neutrophils, and macrophages, protecting the parasite from oxidative damage. Protease inhibitors such as cystatin (CPI-2), serpin (SPN-2), and aspartyl protease inhibitor (API-1/Ov33) modulate host proteases, promote IL-10 production by antigen-presenting cells, and inhibit antigen processing, thereby suppressing T-cell responses. Cytokine homologues like macrophage migration inhibitory factor (MIF) and transforming growth factor-beta (TGF-β) skew the immune environment toward anti-inflammatory Th2 profiles and counter host pro-inflammatory signals. Fatty acid-binding proteins (FAR-1/Ov20) may also contribute by sequestering host lipids essential for immune cell function.

References

[1]
DPDx - Onchocerciasis - CDC
The agent of river blindness, Onchocerca volvulus, occurs mainly in Africa, with additional foci in Latin America and the Middle East. Clinical Presentation.
[2]
Onchocerciasis - World Health Organization (WHO)
Jan 29, 2025 · Onchocerciasis, commonly known as “river blindness”, is caused by the parasitic worm Onchocerca volvulus. The parasite is spread and ...
[3]
Taxonomy browser Taxonomy Browser (Onchocerca volvulus) - NCBI
THE NCBI Taxonomy database allows browsing of the taxonomy tree, which contains a classification of organisms.
[4]
Onchocerca - an overview | ScienceDirect Topics
The name Onchocerca was derived from a combination of the Greek word 'Onchos' meaning 'hook' and 'Kerkos' or 'Cercos' meaning 'tail' [15]. Humans are the only ...
[5]
Zoonotic Implications of Onchocerca Species on Human Health - PMC
Sep 17, 2020 · Another possibility is that O. ochengi may have settled in humans and evolved to new species, such as O. volvulus. In that case, O. volvulus is ...
[6]
https://www.sciencedirect.com/topics/medicine-and-dentistry/onchocerca
[7]
Drug development for onchocerciasis-the past, the present and the ...
The adult worms were first described in subcutaneous nodules by Leuckart in 1893 (2). These represent the repository of adult worms which produce the mf ...
[8]
One Hundred Years After Its Discovery in Guatemala by Rodolfo ...
One hundred years after its discovery in Guatemala by Rodolfo Robles, Onchocerca volvulus transmission has been eliminated from the central endemic zone.
[9]
[PDF] CASE 6 - Controlling Onchocerciasis in Sub-Saharan Africa
The seeds of the first regional OCP were planted in the small-scale control efforts of the 1950s and. 1960s and codified at an international conference held ...
[10]
[PDF] 210867Orig1s000 | FDA
Mar 14, 2018 · The activity of moxidectin was reported against the microfilariae of two of the Onchocerca species as well as the microfilariae and/or adult ...
[11]
Onchocerca volvulus: the road from basic biology to a vaccine - PMC
In the subcutaneous nodules, the female worms are capable of producing microfilariae for approximately 9 years. The microfilariae, measuring 220 to 360 μm by 5 ...Missing: 220-330 | Show results with:220-330
[12]
Morphology of Onchocerca volvulus - Oxford Academic
Male and female worms were reconstructed from serial paraffin sections, and the morphologic features of the adult worms and microfilariae described.Missing: review | Show results with:review
[13]
Pathogenesis and host responses in human onchocerciasis
Onchocerca volvulus is a tissue-invasive parasitic nematode causing skin and eye pathology in human onchocerciasis. The filariae habour abundant ...
[14]
Onchocerca volvulus | INFORMATION - Animal Diversity Web
Scientific Classification ; Phylum, Nematoda roundworms ; Class, Secernentea ; Order, Spirurida ; Family, Filariidae.
[15]
Onchocerciasis - StatPearls - NCBI Bookshelf - NIH
Onchocerciasis, or river blindness, is caused by the nematode *Onchocerca volvulus*, transmitted by black fly bites, and is the second most common cause of ...
[16]
Establishment of an in vitro culture system to study the ...
Feb 9, 2021 · Our study has established an in vitro platform capable of supporting the growth and development of Onchocerca volvulus for up to 315 days.Missing: dimorphism | Show results with:dimorphism
[17]
Importance of ivermectin to human onchocerciasis - PubMed Central
volvulus has a lengthy prepatent period (12–16 months) and requires a black ... Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment.
[18]
Onchocerciasis: Current knowledge and future goals - Frontiers
It is also called river blindness because the Blackflies that transmit infection breeds in rapidly flowing fresh water streams and rivers. This review features ...
[19]
Pathogenesis of Onchocercal Keratitis (River Blindness) - PMC
Although the exact mode of penetration from the skin into the eye is not known, studies by Duke and Garner demonstrated that microfilariae can migrate from the ...
[20]
Lymphatic Vascularisation and Involvement of Lyve-1+ ...
Dec 9, 2009 · In onchocerciasis a subcutaneous nodule is formed around the female worms, the core of which is a dense infiltrate of inflammatory cells in ...Missing: uptake | Show results with:uptake
[21]
Neurological manifestations in Onchocerca volvulus infection
This disease is caused by the filarial nematode Onchocerca volvulus, which is transmitted by female blackflies of the genus Simulium (Boussinesq, 1997). Female ...Missing: taxonomy | Show results with:taxonomy
[22]
Onchocerciasis: the Role of Wolbachia Bacterial Endosymbionts in ...
Summary: The discovery of Wolbachia intracellular bacteria within filarial nematodes, including Onchocerca volvulus, the causative agent of onchocerciasis ...
[23]
Human filarial Wolbachia lipopeptide directly activates human ...
The host inflammatory response to the Onchocerca volvulus endosymbiont, Wolbachia, is a major contributing factor in the development of chronic pathology in ...
[24]
Wolbachia- and Onchocerca volvulus-Induced Keratitis (River ...
Wolbachia bacteria are essential for the pathogenesis of O. volvulus-induced keratitis, since (i) corneal inflammation was not induced by extracts derived from ...
[25]
Innate immune responses to endosymbiotic Wolbachia bacteria in ...
Jan 15, 2007 · These results establish that the innate inflammatory pathways activated by endosymbiotic Wolbachia in B. malayi and O. volvulus filaria are dependent on TLR2- ...
[26]
Nodding syndrome may be an autoimmune reaction to the parasitic ...
An increased rate of nodding syndrome in areas where the parasite Onchocerca volvulus is endemic led to the hypothesis that the infection may play a role in ...
[27]
Systemic and cerebrospinal fluid immune and complement ...
Nodding syndrome is a poorly understood epileptic encephalopathy characterized by a unique seizure type—head nodding—and associated with Onchocerca volvulus ...
[28]
Symptoms of Onchocerciasis | Filarial Worms - CDC
May 13, 2024 · Many people infected with onchocerciasis never develop symptoms. · Common symptoms include vision loss, skin rashes, and lumps under the skin.Missing: volvulus | Show results with:volvulus
[29]
Onchodermatitis: Where Are We Now? - PMC - PubMed Central - NIH
Onchocerciasis causes debilitating pruritus and rashes as well as visual impairment and blindness. Prior to control measures, eye disease was particularly ...
[30]
Chagas Disease, Lymphatic Filariasis, Onchocerciasis, and Leprosy
This chapter focuses on four tropical diseases—Chagas disease, lymphatic filariasis (LF), onchocerciasis, and leprosy—for which effective means of control are ...<|separator|>
[31]
The onchocerciasis hypothesis of nodding syndrome - PMC
Aug 17, 2023 · Nodding syndrome (NS) is a phenotypic presentation of onchocerciasis-associated epilepsy (OAE). OAE is an important public health problem in areas with high ...
[32]
Diagnosis of Onchocerciasis | Filarial Worms - CDC
May 14, 2024 · Skin snips are the most common ways of diagnosing onchocerciasis. · A healthcare professional will example your skin under a microscope to look ...
[33]
Diagnostics for onchocerciasis in the era of elimination - PMC
In this review, we summarize the progress that has been made to identify diagnostics that meet the specialized requirements needed to verify onchocerciasis ...
[34]
Comparison of Diagnostic Tests for Onchocerca volvulus in the ... - NIH
Onchocerciasis is diagnosed by detecting microfilariae in skin snips or by detecting OV16 IgG4 antibodies in blood by either enzyme linked immunosorbent assay ...
[35]
Evaluation of an OV-16 IgG4 Enzyme-Linked Immunosorbent Assay ...
This OV-16 IgG4 ELISA had sensitivity and specificity of 88.2% and 99.7%, respectively, as determined by receiver operator characteristic analysis using a serum ...
[36]
Immunoglobulin G subclass responses of children during infection ...
To increase the specificity of the response, recombinant antigens OV11, OV27, and OV29 were tested individually or as a cocktail. Nearly 50% of the MF-negative ...
[37]
Detection of Onchocerca volvulus infection by O-150 polymerase ...
A polymerase chain reaction (PCR)-based assay was shown to detect the presence of parasite DNA in superficial skin scrapings.
[38]
RECOMMENDATIONS - NCBI - NIH
The Ov-16 serology test should be used in children less than 10 years of age to demonstrate the interruption of transmission of O. volvulus in a human ...
[39]
From river blindness control to elimination: bridge over troubled water
Mar 28, 2018 · Moreover, health care providers working in remote endemic zones may fail to diagnose onchocerciasis due to insufficient training and poor ...
[40]
Clinical Treatment of Onchocerciasis | Filarial Worms - CDC
May 13, 2024 · The treatment of choice for onchocerciasis is ivermectin, which has shown to reduce the occurrence of blindness and to reduce the occurrence and severity of ...
[41]
Ivermectin (oral route) - Side effects & dosage - Mayo Clinic
Feb 1, 2025 · The dose is usually 150 micrograms (mcg) per kilogram (kg) of body weight taken as a single dose. The treatment may be repeated every 3 to 12 ...
[42]
Depletion of wolbachia endobacteria in Onchocerca volvulus by ...
Here we show that additional treatment with doxycycline, previously shown to sterilise adult female worms for a few months by depletion of symbiotic wolbachia ...
[43]
Doxycycline Leads to Sterility and Enhanced Killing of Female ...
Targeting the Wolbachia in O. volvulus is effective in clearing microfilariae in the skin of onchocerciasis patients with persistent microfilaridermia and in ...Abstract · METHODS · RESULTS · DISCUSSION
[44]
Onchocerciasis (River Blindness) Treatment & Management
Feb 24, 2025 · Repeated dosing at intervals of 3–12 months is recommended for at least 10-12 years. More frequent dosing is reserved for patients who ...
[45]
The reduction in microfilariae loads in the skin and eye after ...
Surgical removal of nodules reduces the microfilarial loads in 40 of 46 patients studied over a period of five months, with an average reduction of 65.4% of the ...Missing: treatment | Show results with:treatment
[46]
First new treatment for river blindness approved by U.S. FDA in 20 ...
Jun 14, 2018 · The United States Food and Drug Administration (FDA) has approved moxidectin as the first new treatment for river blindness in 20 years.
[47]
2024 R&D programmes in review: Filaria – river blindness - DNDi
Mar 4, 2025 · Emodepside: By the third quarter of 2024, all enrolled patients had completed treatment and follow-up in part 1 of the Phase II study testing ...<|separator|>
[48]
Oxfendazole for river blindness - DNDi
The study is examining the safety and efficacy of oxfendazole in treating multiple helminthic diseases, including onchocerciasis, loiasis, mansonellosis, and ...
[49]
Persistence of onchocerciasis and associated dermatologic and ...
Oct 17, 2023 · In Ghana and Cameroon, sub-optimal responses to ivermectin have been reported phenotypically and using genome-wide analysis approaches in ...
[50]
Does dexamethasone suppress the Mazzotti reaction in patients ...
The Mazzotti reaction is a frequent complication in patients with onchocerciasis being treated with diethylcarbamazine (DEC); and more severe manifestations ...
[51]
Prevention, control and elimination of Onchocerciasis
Its strategy is the provision of mass drug administration (MDA) with ivermectin tablets at least twice a year to all communities in endemic areas, reaching at ...
[52]
Onchocerciasis and its control: WHO TRS N°852
The opening sections summarize current knowledge of the filarial parasite Onchocerca volvulus and the blackfly vectors. Five sections profile current ...
[53]
[PDF] Entomological manual for onchocerciasis elimination programmes
Correct identification of O. volvulus vectors in Africa is crucial for successful elimination programmes in order to monitor progress, confirm interruption of ...
[54]
Use of Ov16-Based Serology for Post-Elimination Surveillance of ...
Ov16-based serology offers an economic and practical alternative for measuring vector infectivity for post-certification surveillance in formerly endemic ...
[55]
[PDF] Screening for Onchocerca volvulus Anti-Ov16 IgG4 Response
In 2014, SD BIOLINE® Onchocerciasis IgG4 RDT was launched as a surveillance tool for identifying exposure to O. volvulus by detecting anti-Ov16 IgG4.(26) It ...
[56]
Integrating national programmes to eliminate lymphatic filariasis and ...
Feb 8, 2015 · Dr Jonathan King explained the need for clear procedures on how best to integrate and coordinate the activities recommended by WHO.Missing: approaches | Show results with:approaches
[57]
Impact assessment of onchocerciasis through lymphatic filariasis ...
Mar 11, 2024 · In 2007, the NOCP became the National Neglected Tropical Disease Program (NNTDP), and onchocerciasis treatment was integrated with albendazole ...
[58]
Feasibility of Onchocerciasis Elimination Using a “Test-and-not-treat ...
Therefore, ivermectin MDA is not recommended in areas where onchocerciasis is hypo-endemic and L loa is co-endemic. To eliminate onchocerciasis in those areas, ...
[59]
River Blindness: A Success Story under Threat? - PMC
Sep 26, 2006 · O. volvulusis endemic in 27 sub-Saharan African countries, the Yemen [7], and was imported through the slave trade to six Latin American ...
[60]
Genomic diversity in Onchocerca volvulus and its Wolbachia ...
We describe O. volvulus genome variation in 27 isolates from early 1990s (before widespread mass treatment) from four distinct locales.Missing: taxonomy | Show results with:taxonomy
[61]
WHO verifies Niger as the first country in the African Region to ...
Jan 30, 2025 · Niger joins four other countries that have been verified by WHO for eliminating onchocerciasis, all in the Region of the Americas: Colombia ( ...
[62]
River blindness: a devastating yet neglected tropical disease in Africa
Feb 7, 2025 · Diagnosis of onchocerciasis remains a challenge and the NTD Diagnostics Technical Advisory Group identified development of new diagnostic tools ...
[63]
Onchocerciasis - "River Blindness" - PAHO/WHO
Onchocerciasis is a parasitic disease caused by the filarial nematode worm Onchocerca volvulus. It is transmitted to humans by black flies (genus Simulium)
[64]
Serological Evaluation of Onchocerciasis and Lymphatic Filariasis ...
Endemicity levels are defined as follows: hypoendemic = microfilarial (mf) prevalence <40%, mesoendemic = mf prevalence ≥40% but <60%, and hyperendemic = mf ...
[65]
Biting Rates and Onchocerca Infectivity Status of Black Flies from the ...
May 4, 2020 · However, annual biting rates exceeded the World Health Organization threshold of 1,000 bites/person/yr. Thus it appears that, with such high ...Missing: 200-1000 | Show results with:200-1000
[66]
Onchocerca volvulus transmission in the Mbam valley of Cameroon ...
Nov 2, 2021 · The lesser peak occurs between March and June which precedes a brief dry period in July and is followed by heavier rainfall between August and ...
[67]
Projected Number of People With Onchocerciasis–Loiasis ...
By 2025, we predict that about 2000 coinfected cases with L. loa hypermicrofilaremia will remain in treated areas. This represents only 0.002% of the total ...
[68]
The current status of onchocerciasis in the forest/savanna transition ...
Onchocerca volvulus exists in at least two strains in West Africa, while its black-fly vectors consist of sibling species, dwelling in the savanna and forest/ ...Missing: ecological | Show results with:ecological
[69]
Vector-parasite transmission complexes for onchocerciasis in West ...
Genomic DNA was extracted from larvae, and PCR amplification was used to classify O volvulus parasites as forest or savanna strains. PCR-amplified DNA from ...<|separator|>
[70]
The Impact of Onchocerciasis Elimination Measures in Africa
Dec 26, 2024 · According to WHO estimates, it has prevented the infection of 40 million people, prevented 600,000 people from blindness, and allowed 18 million ...
[71]
Recrudescence of transmission of onchocerciasis in some endemic ...
Over 99% of all cases of onchocerciasis and onchocercal-related blindness are found in Africa; with Nigeria having about 40% of the global population at risk [3] ...Missing: trends | Show results with:trends
[72]
Progress toward elimination of onchocerciasis in the Americas
Feb 19, 2018 · In 2013, Colombia was the first country in the world to be verified free of onchocerciasis transmission by the WHO under the 2001 guidelines.
[73]
Colombia: River Blindness Elimination Proof of Concept
Apr 11, 2018 · In 2013, Colombia was the first country in the world where elimination of onchocerciasis was verified by WHO [26], followed by Ecuador in 2014 ...Ivermectin Mass Drug... · Serological Studies · Author InformationMissing: milestones | Show results with:milestones
[74]
WHO verifies Mexico free of onchocerciasis
Oct 14, 2015 · WHO recommends a strategy of mass treatment with ivermectin (an unlimited supply of which is donated as Mectizan by Merck & Co., Inc.) for the ...
[75]
WHO verifies Guatemala is 4th country to eliminate river blindness
Dec 8, 2016 · Only one focus of onchocerciasis (river blindness) persists in the Americas, on the border between Brazil and Venezuela.
[76]
Progress Toward Onchocerciasis Elimination in Brazil - PubMed
Jul 9, 2024 · Mass drug administration of ivermectin began in 1995, with 36 effective biannual rounds (≥85% coverage of the eligible population) through 2022.
[77]
Report from the Inter-American Conference on Onchocerciasis, 2024
Oct 10, 2025 · Human onchocerciasis (river blindness) is caused by the parasitic worm Onchocerca volvulus, transmitted by Simulium black flies that breed ...
[78]
Elimination of human onchocerciasis: progress report, 2024–2025
Oct 10, 2025 · For onchocerciasis elimination, sustaining high treatment coverage remains critical. Any decline in coverage or interruption in treatment risks ...
[79]
[PDF] onchocerciasis - Mectizan Donation Program
The target audience of these guidelines is policy-makers in endemic countries, national neglected tropical disease or onchocerciasis elimination programmes and ...
[80]
Onchocerciasis control in the Democratic Republic of Congo (DRC ...
Oct 10, 2014 · Conclusions. Challenges to CDTI in DRC have been serious adverse reactions to ivermectin in loiasis co-endemic areas and political conflict.
[81]
Recrudescence of transmission of onchocerciasis in some endemic ...
Aug 7, 2025 · Pooled screen assays of 72 pools heads of black flies were conducted using quantitative polymerase chain reaction (qPCR) for O. volvulus ...<|separator|>
[82]
The World Health Organization road map for neglected tropical ...
May 17, 2021 · The World Health Organization road map for neglected tropical diseases 2021–2030: implications for onchocerciasis elimination programs.
[83]
The genome of Onchocerca volvulus, agent of river blindness - PMC
Nov 21, 2016 · Human onchocerciasis is a serious neglected tropical disease caused by the filarial nematode Onchocerca volvulus that can lead to blindness ...<|control11|><|separator|>
[84]
The genomes of Onchocerca volvulus - PubMed
The nuclear genome is roughly 1.5x10(8) bp in size, and is arranged on four chromosome pairs. Analysis of expressed sequence tags from different life-cycle ...
[85]
The mitochondrial genome of Onchocerca volvulus
The O. volvulus mitochondrial genome contains genes for two ribosomal RNAs, 22 transfer RNAs and 12 proteins. Consistent with the small size of the genome, four ...
[86]
The secretory omega‐class glutathione transferase OvGST3 from ...
Jun 28, 2008 · The first two exons of the ovgst3 gene encode a signal peptide before sequence identity to other omega-class GSTs begins. The predicted cleavage ...Results And Discussion · Protein Sequence Analysis · Immunohistological...
[87]
Onchocerca_volvulus_V1 - Genome - Assembly - NCBI
Onchocerca volvulus (nematodes) genome assembly Onchocerca_volvulus_V1 from Broad Institute [GCA_000180695.1 ]
[88]
Secreted venom allergen-like proteins of helminths - PubMed Central
Oct 18, 2018 · Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce ...Missing: embryogenesis evasion
[89]
The genome of Onchocerca volvulus, agent of river blindness - Nature
Nov 21, 2016 · The O. volvulus Wolbachia 956 kb genome contains 785 predicted protein-coding genes. Comparison of wOv with the published Wolbachia of O.<|control11|><|separator|>
[90]
Wolbachia: endosymbiont of onchocercid nematodes and their vectors
May 7, 2021 · In onchocercid nematodes, Wolbachia has a mutual association in which it is involved in embryogenesis, moulting, growth and survival.Wolbachia As A Modulator Of... · Exploiting Wolbachia For... · Targeting Wolbachia For...
[91]
Reduced variation in Wolbachia density of larval stages in ... - bioRxiv
Oct 31, 2018 · Reduced variation in Wolbachia density of larval stages in comparison with adults of Onchocerca volvulus: implications for clinical outcome of ...
[92]
Wolbachia endobacteria depletion by doxycycline as antifilarial ...
Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study.
[93]
Wolbachia endosymbionts induce neutrophil extracellular trap ...
Oct 18, 2016 · The endosymbiotic bacteria, Wolbachia, induce neutrophilic responses to the human helminth pathogen Onchocerca volvulus.Results · Methods · Whole Wolbachia Purification
[94]
Molecular phylogeny of the filaria genus Onchocerca with special ...
Filarial parasites of the genus Onchocerca are found in a broad spectrum of ungulate hosts. One species, O. volvulus, is a human parasite that can cause ...
[95]
25 Years of the Onchocerca ochengi Model - PubMed
On the basis of both morphological and molecular criteria, O. ochengi is the closest extant relative of O. volvulus and shares several key natural history ...
[96]
Complete mitochondrial genome of Onchocerca lupi (Nematoda ...
Onchocerca lupi, Rodonaja 1967, is an emerging, zoonotic filarial nematode parasite that causes ocular disease in dogs, cats, wild canids, and humans.
[97]
Molecular epidemiology, phylogeny and evolution of the filarial ... - NIH
Aug 29, 2014 · Their phylogeny reveals that speciation from the common ancestor of both B. malayi and Wb occurred around 5–6 millions years ago with shared ...
[98]
Molecular systematics of five Onchocerca species (Nematoda
ochengi is the sister species of O. volvulus, in accordance with the classification based on morphology and geographical location. The separate specific ...
[99]
Shaking the Tree: Multi-locus Sequence Typing Usurps Current ...
Nov 20, 2015 · Filariae are predominantly tissue-dwelling nematodes of the Onchocercidae (Spirurida). They are parasites of terrestrial vertebrates and some of ...
[100]
Multi-locus Sequence Typing Usurps Current Onchocercid (Filarial ...
The present phylogenetic tree supports the accuracy of the Dipetalonema lineage, as all genera included in the clade ONC4, with the exception of Litomosoides, ...
[101]
Onchocerca-Simulium interactions and the population ... - PubMed
Also, parasites and their vectors may co-evolve, giving rise to locally adapted combinations or complexes with the potential to stabilise the infection. Here, ...
[102]
Evolution, epidemiology, and population genetics of black flies ...
We review the evolution and population genetics of the Simuliidae, and provide a case study of the epidemiology of the Simulium damnosum complex.
[103]
Assessing Onchocerca volvulus Intensity of Infection and Genetic ...
Jul 24, 2023 · Ivermectin kills the larval stages (microfilariae) found in the skin of infected persons (microfilaricidal effect), and temporarily stops female ...Missing: dimensions length
[104]
Genome-based tools for onchocerciasis elimination: utility of the ...
In the study reported here, we tested the utility of population genetic markers based on variation in the whole mitochondrial genome of O. volvulus to identify ...Missing: savanna | Show results with:savanna
[105]
Genetic structuring and estimation of reproductive adults in ...
Genome-based tools for onchocerciasis elimination: utility of the mitochondrial genome for delineating Onchocerca volvulus transmission zones. Int J ...
[106]
Full mitochondrial and nuclear genome comparison confirms that ...
The mitochondrial gene content and order (Fig. 1) is the same as in O. volvulus (Keddie et al. 1998) with 12 protein-coding genes, 22 tRNA genes, and coding ...Missing: size | Show results with:size
[107]
Zoonotic Implications of Onchocerca Species on Human Health - MDPI
Sep 17, 2020 · In this work, we discuss the establishment of zoonotic Onchocerca infections in humans, and the possibility of these infections to produce symptoms similar to ...
[108]
Protective Immunity to the Larval Stages of Onchocerca volvulus Is ...
Thus, protective immunity against O. volvulus is dependent on a Th2 immune response and is mediated by eosinophils and IgE. Toll-like receptors (TLRs) recognize ...Missing: innate | Show results with:innate
[109]
Onchocerca volvulus microfilariae avoid complement attack by direct ...
Thus, mf of the nematode O. volvulus may evade human complement by binding fH and by promoting inactivation of C3b into iC3b. Publication types. Research ...
[110]
Onchocerca volvulus-specific antibody and cellular responses in ...
May 3, 2022 · Such lower innate responsiveness in elderly patients could contribute to reduced adaptive immune responses to parasite infections and vaccines.
[111]
Onchocerciasis Fingerprints in the Geriatric Population: Does Host ...
Indeed, Onchocerca volvulus has been reported to counteract the immune responses of the host through molecular mimicry by impairing T-cell activation and ...<|control11|><|separator|>
[112]
HLA-D alleles associated with generalized disease, localized ...
HLA-D alleles associated with generalized disease, localized disease, and putative immunity in Onchocerca volvulus infection. · C G Meyer · M Gallin · K D Erttmann.
[113]
Revisiting the Mechanisms of Immune Evasion Employed by Human ...
The parasites' immune evasion mechanisms can be categorized into several strategies ... Onchocerca volvulus Microfilariae Avoid Complement Attack by Direct ...
[114]
https://pmc.ncbi.nlm.nih.gov/articles/PMC8396225/
[115]
https://pmc.ncbi.nlm.nih.gov/articles/PMC44432/
[116]
https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.702125/full
[117]
https://doi.org/10.1086/340649
[118]
https://doi.org/10.1016/s1286-4579(02)00014-x
[119]
https://doi.org/10.4049/jimmunol.0904067